Xencor’s (XNCR) Outperform Rating Reiterated at Royal Bank of Canada

Royal Bank of Canada reiterated their outperform rating on shares of Xencor (NASDAQ:XNCR) in a research note published on Tuesday morning, Benzinga reports. The brokerage currently has a $31.00 price target on the biopharmaceutical company’s stock.

Other equities analysts have also issued research reports about the stock. Raymond James reduced their price target on shares of Xencor from $58.00 to $40.00 and set a strong-buy rating for the company in a research report on Friday, June 14th. BMO Capital Markets reiterated an outperform rating and set a $32.00 target price on shares of Xencor in a research report on Tuesday. JPMorgan Chase & Co. cut their target price on shares of Xencor from $30.00 to $27.00 and set an overweight rating for the company in a research report on Wednesday, July 31st. Wedbush reiterated an outperform rating and set a $34.00 target price (down previously from $36.00) on shares of Xencor in a research report on Thursday, June 13th. Finally, BTIG Research cut their target price on shares of Xencor from $56.00 to $38.00 and set a buy rating for the company in a research report on Tuesday, April 16th. Two investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of Moderate Buy and an average price target of $34.44.

Xencor Trading Up 2.3 %

NASDAQ:XNCR opened at $16.06 on Tuesday. The firm’s fifty day moving average is $20.10 and its 200-day moving average is $21.20. The company has a debt-to-equity ratio of 0.02, a quick ratio of 7.08 and a current ratio of 6.92. Xencor has a 52 week low of $15.31 and a 52 week high of $26.84. The firm has a market cap of $990.26 million, a P/E ratio of -7.33 and a beta of 0.69.

Xencor (NASDAQ:XNCR) last announced its earnings results on Monday, August 5th. The biopharmaceutical company reported ($1.07) EPS for the quarter, missing the consensus estimate of ($0.82) by ($0.25). The firm had revenue of $16.96 million during the quarter, compared to analysts’ expectations of $21.13 million. Xencor had a negative net margin of 132.74% and a negative return on equity of 28.23%. The business’s revenue for the quarter was down 62.7% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.37) EPS. Equities analysts expect that Xencor will post -3.56 earnings per share for the current year.

Insider Transactions at Xencor

In related news, VP John R. Desjarlais sold 36,329 shares of the firm’s stock in a transaction that occurred on Tuesday, July 9th. The shares were sold at an average price of $18.32, for a total value of $665,547.28. Following the sale, the vice president now directly owns 192,319 shares of the company’s stock, valued at $3,523,284.08. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 5.23% of the company’s stock.

Institutional Investors Weigh In On Xencor

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. CWM LLC raised its stake in shares of Xencor by 498.7% during the fourth quarter. CWM LLC now owns 1,377 shares of the biopharmaceutical company’s stock worth $29,000 after acquiring an additional 1,147 shares in the last quarter. Parallel Advisors LLC raised its stake in shares of Xencor by 303.9% during the fourth quarter. Parallel Advisors LLC now owns 1,349 shares of the biopharmaceutical company’s stock worth $29,000 after acquiring an additional 1,015 shares in the last quarter. Signaturefd LLC raised its stake in shares of Xencor by 367.7% during the fourth quarter. Signaturefd LLC now owns 1,464 shares of the biopharmaceutical company’s stock worth $31,000 after acquiring an additional 1,151 shares in the last quarter. GAMMA Investing LLC raised its stake in shares of Xencor by 153.7% during the first quarter. GAMMA Investing LLC now owns 2,172 shares of the biopharmaceutical company’s stock worth $48,000 after acquiring an additional 1,316 shares in the last quarter. Finally, Allworth Financial LP raised its stake in shares of Xencor by 29,487.5% during the fourth quarter. Allworth Financial LP now owns 2,367 shares of the biopharmaceutical company’s stock worth $50,000 after acquiring an additional 2,359 shares in the last quarter.

Xencor Company Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.